Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Jun 21, 2020 8:46am
57 Views
Post# 31174010

RE:Questions for BOD/Management AGM submitted

RE:Questions for BOD/Management AGM submitted Longterm if GBT does not have great new upcoming drugs coming out of their pipeline GUD is toasted and GUD MNGT has made a financial mortal mistake. It may take LATAM over a decade if, to come out of the damage caused by Covid-19. So the fundamental question is.
What drugs GBT has in the pipeline and timeline. If GUD MNGT in the AGM omits and does not voluntarily offer detailed information on this topic you what the answers is. They F k ed up  but will they never admit and they will go on with bs narratives changes of of the past. Let’s hope I am 100% . What they not say is what wories me. 
Bullboard Posts